Evidence map›Paper›PMID 28696020›Full record

ReviewPediatric blood & cancer2017

Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.

Caryn Sorge, Rong Li, Sumit Singh, Alyssa T Reddy, David A Solomon, Arie Perry, Gregory K Friedman

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in Pediatric blood & cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Caryn SorgeDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.
Rong LiDepartment of Pathology, Children's of Alabama, Birmingham, Alabama.
Sumit SinghDepartment of Radiology, Children's of Alabama, Birmingham, Alabama.
Alyssa T ReddyDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.
David A SolomonDepartment of Pathology, University of California San Francisco, San Francisco, California.
Arie PerryDepartment of Pathology, University of California San Francisco, San Francisco, California.
Gregory K FriedmanDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.ORCID http://orcid.org/0000-0002-6653-7420
University of Alabama at Birmingham · USChildren's of Alabama · USUniversity of California, San Francisco · US

Funding

Cohesin gene mutations in tumorigenesisDP5OD021403 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SOLOMON, DAVID A. · 2015 to 2019
$2.0M
NIH HHS DP5 OD021403
6 · The paper itself

Abstract

Anaplastic oligodendroglioma (AO) is rare in children. Treatment typically consists of varying combinations of surgery, chemotherapy, and radiotherapy. We present a pediatric case of frontal lobe AO with periventricular subcallosal extension and local leptomeningeal involvement. The isocitrate dehydrogenase (IDH) wild-type tumor was MGMT methylated and contained an ATRX mutation, BRAF alteration, and 1p/19q co-deletion; a combination of alterations mostly encountered in pediatric oligodendrogliomas. The patient underwent a near total resection and had a complete, durable response to temozolomide alone, suggesting that conservative management without radiation may be appropriate in some cases. We review the literature of this uncommon subtype of glioma in children.

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsChildDacarbazineHumansIsocitrate DehydrogenaseMaleOligodendrogliomaTemozolomideAntineoplastic Agents, AlkylatingDacarbazineIsocitrate DehydrogenaseTemozolomide1p19qchildrencodeletionoligodendrogliomapediatrictemozolomide

Identifiers

PMID28696020
PMCPMC8408833
OpenAlexW2735099033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.